Company profile for AM-Pharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

AM-Pharma is developing a treatment for acute kidney injury (AKI) that could be life saving. AM-Pharma is a clinical stage biopharmaceutical company, leading in the development of a treatment for AKI with its innovative recombinant human Alkaline Phosphatase therapeutic (recAP). AKI is a devastating disease with high mortality rate that affects millions of patients worldwide. There is no approved pharmacological treatment for...
AM-Pharma is developing a treatment for acute kidney injury (AKI) that could be life saving. AM-Pharma is a clinical stage biopharmaceutical company, leading in the development of a treatment for AKI with its innovative recombinant human Alkaline Phosphatase therapeutic (recAP). AKI is a devastating disease with high mortality rate that affects millions of patients worldwide. There is no approved pharmacological treatment for AKI and our biologic, recAP, has the potential to be a first-in-class medicine.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Netherlands
Address
Address
Stadsplateau 6, 3521 AZ Utrecht, The Netherlands The Netherlands
Telephone
Telephone
+ 31 (0)30 228 92 22
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/10/02/3160168/0/en/AM-Pharma-Completes-Enrollment-in-Phase-2-Study-of-Ilofotase-Alfa-for-Prevention-of-Cardiac-Surgery-Associated-Renal-Damage.html

GLOBENEWSWIRE
02 Oct 2025

https://www.businesswire.com/news/home/20240116554554/en

BUSINESSWIRE
16 Jan 2024

https://www.businesswire.com/news/home/20231011995076/en

BUSINESSWIRE
11 Oct 2023
AM-Pharma cuts staff, CEO leaves as lead asset redirected
AM-Pharma cuts staff, CEO leaves as lead asset redirected

27 Sep 2023

// Annalee Armstrong FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/am-pharma-cuts-staff-says-goodbye-ceo-lead-kidney-injury-asset-redirected

Annalee Armstrong FIERCE BIOTECH
27 Sep 2023

https://www.businesswire.com/news/home/20230926795228/en

BUSINESSWIRE
26 Sep 2023

https://www.businesswire.com/news/home/20230309005027/en

BUSINESSWIRE
09 Mar 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty